Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | SMPD3 | Q9NY59 | 4/20 | 0.38 |
| ▸ | CDK4 | P11802 | 2/20 | 0.38 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CHKA | P35790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20133003 | 0.87 | CDK4 (0.40) | MAPTCDK4CDK6ALDH1A1MAPK1 | |
| SCHEMBL16943593 | 0.84 | GRM2 (0.45) | MAPTSMPD3CDK4CDK6PARP1 | |
| SCHEMBL18354211 | 0.80 | MAPT (0.42) | MAPTSMPD3CDK4CDK6PARP1 | |
| SCHEMBL20133346 | 0.74 | CCNC (0.42) | MAPTHIPK2ALDH1A1MAPK1TDP1 | |
| SCHEMBL18354208 | 0.73 | MAPT (0.44) | MAPTPARP1ALDH1A1 | |
| SCHEMBL18354815 | 0.71 | MAPT (0.48) | MAPTSMPD3POLBCCNCCDK8 | |
| SCHEMBL16942998 | 0.71 | MAPT (0.43) | MAPTCDK4CDK6PARP1ALDH1A1 | |
| SCHEMBL18381094 | 0.71 | MAPT (0.43) | MAPTCDK4PARP1GRM2ALDH1A1 | |
| SCHEMBL18354319 | 0.70 | MAPT (0.46) | MAPTCDK4CDK6GRM2ALDH1A1 | |
| SCHEMBL16943377 | 0.70 | MAPT (0.46) | MAPTCDK4CDK6GRM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | MAPT 5/4885SMPD3 4561/4885CDK4 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.